irinotecan has been researched along with Triple Negative Breast Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 10 (47.62) | 2.80 |
| Authors | Studies |
|---|---|
| Bargh-Dawson, H; Brown, E; Gerrard, J; Hughes, AM; Jones, GN; Lau, A; O'Connor, MJ; Odedra, R; Wallez, Y; Wijnhoven, PWG; Wilson, Z; Young, LA | 1 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
| Furlanetto, J; Loibl, S; Marmé, F | 1 |
| Hamilton, E; Jacob, S; Rugo, HS; Shastry, M | 1 |
| Chalasani, P; Cordova, LE; Lu, J; Wang, Z | 1 |
| Bièche, I; Briaux, A; Château-Joubert, S; Coussy, F; Dahmani, A; Decaudin, D; El-Botty, R; Foidart, P; Fuhrmann, L; Huguet, L; Jonkers, J; La Rosa, P; Larcher, T; Leboucher, S; Lucotte, G; Marangoni, E; Montaudon, E; Morisset, L; Mueller, C; Nemati, F; Noel, A; Painsec, P; Pommier, Y; Popova, T; Poupon, MF; Reyal, F; Reyes, C; Salomon, A; Servely, JL; Sounni, NE; Sourd, L; Stern, MH; Ter Brugge, P; Vacher, S | 1 |
| Cao, H; Guo, XY; Jia, YF; Jiang, L; Jing, MX; Sun, T; Wang, Y; Ying, E | 1 |
| Anders, C; Belanger, B; Han, HS; Ma, C; Maxwell, F; Moore, Y; Munster, P; Northfelt, DW; Sachdev, JC; Thiagalingam, A; Wang, T; Zhang, B | 1 |
| Amrahli, M; Cressey, P; Gedroyc, W; So, PW; Thanou, M; Wright, M | 1 |
| Ata, FK; Yalcin, S | 1 |
| Hosoda, Y; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Adkins, CE; Dolan, EL; Griffith, JI; Hendriks, BS; Lee, H; Lockman, PR; Mohammad, AS; Sechrest, E; Shah, N; Terrell-Hall, TB | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
| Bernards, N; Fitzgerald, J; Fricke, IB; Hendriks, BS; Lee, H; Ventura, M; Zheng, J | 1 |
| Barrett, JC; Cadogan, EB; Garcia-Trinidad, A; Griffin, N; Harrington, EA; Howat, WJ; Hughes, GD; Ivey, RG; Jones, GN; Lau, A; Odedra, R; Paulovich, AG; Pierce, AJ; Ramos-Montoya, A; Rooney, C; Roudier, M; Whiteaker, JR; Wilson, Z; Young, LA; Zhao, L | 1 |
| Abramson, VG; Bardia, A; Diamond, JR; Goldenberg, DM; Iannone, R; Isakoff, SJ; Kalinsky, K; Mayer, IA; Moroose, RL; O'Shaughnessy, J; Rugo, HS; Santin, AD; Shah, NC; Sharkey, RM; Sweidan, AM; Tolaney, SM; Vahdat, LT; Washkowitz, S; Wegener, WA | 1 |
| Ashley, GW; Fontaine, SD; Hann, B; Reid, R; Santi, DV | 1 |
| Abramson, V; Anders, C; Berg, J; Carey, LA; Carpenter, JT; Deal, AM; Karginova, O; Kelly Marcom, P; Lin, NU; Liu, MC; Melhem-Bertrandt, A; Melisko, M; Nanda, R; Parker, J; Perou, CM; Peterman, A; Prat, A; Puhalla, S; Smith, JK; Stearns, V; Storniolo, AM; Van Poznak, C; Winer, EP; Wolff, AC | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Boerner, JL; Boerner, SA; Burger, A; Heilbrun, L; LoRusso, PM; Mueller, KL; Nechiporchik, N; Polin, L; Stark, K; Zoratti, GL | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Rossi, EA; Sharkey, RM | 1 |
1 review(s) available for irinotecan and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Hormones; Humans; Immunoconjugates; Irinotecan; Triple Negative Breast Neoplasms | 2022 |
5 trial(s) available for irinotecan and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Topoisomerase Inhibitors; Triple Negative Breast Neoplasms | 2022 |
Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial.
Topics: China; Combined Modality Therapy; Cost-Benefit Analysis; Diet, Ketogenic; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Irinotecan; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Progression-Free Survival; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
15 other study(ies) available for irinotecan and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carboplatin; Humans; Indoles; Irinotecan; Morpholines; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sulfoxides; Triple Negative Breast Neoplasms | 2022 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |
Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
Topics: B7-H1 Antigen; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interferon-gamma; Irinotecan; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Topics: Humans; Irinotecan; Nuclear Proteins; Retinoblastoma Binding Proteins; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases | 2020 |
Image-guided thermosensitive liposomes for focused ultrasound enhanced co-delivery of carboplatin and SN-38 against triple negative breast cancer in mice.
Topics: Animals; Carboplatin; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Mice; Triple Negative Breast Neoplasms | 2021 |
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Proteins; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |
[A Case of Triple Negative Spindle Cell Carcinoma of the Breast and Improved Quality of Life Following Irinotecan Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Camptothecin; Carcinoma; Female; Humans; Irinotecan; Middle Aged; Quality of Life; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Female; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Nude; Nanoparticles; Permeability; Tissue Distribution; Topoisomerase I Inhibitors; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |
Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Topics: Animals; Cell Line, Tumor; Female; Irinotecan; Liposomes; Magnetic Resonance Imaging; Mice; Mice, SCID; Triple Negative Breast Neoplasms; Tumor Burden | 2018 |
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Cell Line; DNA Damage; Humans; Immunohistochemistry; Indoles; Irinotecan; Mass Spectrometry; Mice; Mice, Nude; Morpholines; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinolines; Signal Transduction; Sulfonamides; Sulfoxides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Drug Liberation; Half-Life; Irinotecan; Macromolecular Substances; Metabolic Clearance Rate; Mice; Polyethylene Glycols; Prodrugs; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Female; Humans; Immunoconjugates; Irinotecan; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |